China Unveils 2030 Pharma Plan Targeting 3.5 Trillion Yuan Revenue

Ten Chinese government ministries, led by the Ministry of Industry and Information Technology, have jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry. The blueprint sets quantitative benchmarks through 2030, targeting annual revenues among major pharmaceutical enterprises to surpass 3.5 trillion yuan, with the innovative drug sector projected to grow at an average annual rate exceeding 20 percent. The strategy also calls for China to account for more than 25 percent of global first-in-class drug candidates, nurture 50 enterprises with annual revenue exceeding 10 billion yuan, and produce at least five global blockbuster drugs with annual sales topping 1 billion dollars.

The 15th Five-Year Plan transitions China's biopharmaceutical strategy from generic volume and incremental innovation toward originative breakthroughs. Setting clear numerical benchmarks for first-in-class therapies and blockbuster revenues signals a structured national push to elevate domestic biotechnology into an internationally competitive, high-margin export engine. Reaching these targets will require substantive coordination across drug review agencies, medical insurance reimbursement, and commercial capital channels.

Ten Chinese government agencies, led by the Ministry of Industry and Information Technology (MIIT) alongside the National Development and Reform Commission (NDRC), have jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry, according to state media reports published on September 18. The strategic roadmap outlines quantitative goals through 2030 designed to elevate biopharmaceuticals into an emerging national pillar industry. Under the plan, total operating revenue for pharmaceutical enterprises above a designated scale is projected to exceed 3.5 trillion yuan (approximately 490 billion dollars). Simultaneously, the innovative medicine segment is targeted to achieve an average annual growth rate of more than 20 percent across the planning cycle. Technological innovation forms the core of the newly announced targets. According to reports from Xinhua and the Securities Times, the plan stipulates that publicly listed pharmaceutical enterprises should maintain an average research and development expenditure intensity of at least 10 percent annually. Beijing also expects domestic developers to account for more than 25 percent of all first-in-class (FIC) drug candidates worldwide, while achieving the market launch of at least 200 innovative medical devices. To consolidate industry competitiveness, the policy document outlines structural targets for corporate scale and regional concentration. By 2030, the government aims to cultivate 50 pharmaceutical enterprises with annual operating revenues exceeding 10 billion yuan, develop 20 industrial clusters reaching 100 billion yuan in annual output, and see at least five domestically developed products attain global annual sales exceeding 1 billion dollars. According to data from the MIIT's Consumer Goods Industry Department cited by People's Daily, the sector has already laid substantial groundwork, with 230 innovative drugs and 292 innovative medical devices reaching commercial approval in recent years, placing China's active drug development pipeline second globally. The plan defines 25 priority tasks spread across eight key operational dimensions, including strengthening supply chain resilience, accelerating clinical translation, advancing digital and intelligent manufacturing, and reinforcing public health supply security. Authorities explicitly noted plans to integrate computational medicine, artificial intelligence, and quantum computing into discovery workflows, while advancing frontiers such as organ-on-a-chip platforms, gene editing, and space pharmaceuticals. The MIIT stated that inter-ministerial coordination will be utilized to align industrial policy, regulatory approvals, national insurance reimbursement, and financial support.